Pending validation of humanized mice, syngeneic mouse models continue to be essential to reveal the impact of PRL as well as other agents on inflammation and suppression of anti-tumor immunity, a critical step toward employment of the promise of immunotherapies for hormonally responsive cancers. This evidence concerns the gene PRL and cancer.